South Africa’s medical cannabis landscape is witnessing a breakthrough, led by Dr. Shiksha Gallow. Known for completing South Africa’s first Pharma-ethics and DOH-approved clinical trials, Dr. Gallow is now a globally sought-after speaker. Her latest engagements include the CIU Australian Medical Cannabis Conference in Brisbane, marking her rising influence in international medical cannabis research.
Global Recognition for Groundbreaking Research
Dr. Gallow’s work has caught international attention. In October 2024, she presented at the SCC Conference in Baltimore, USA. She expanded her influence by opening a Holistic Healing branch in Costa Rica and participating in keynote sessions in Thailand and the Philippines. Notably, she advocated for medical cannabis legalization during a workshop in Manila, highlighting its potential benefits for the Philippines’ population.
Strategic Partnerships and Future Trials
In January 2025, Dr. Gallow took on the role of Medical Director at GET Pharmaceuticals. This Gauteng-based GMP facility aims to become a leading cannabis processor and exporter. At the UIC 2025 Australian Medical Cannabis Symposium in Brisbane, Dr. Gallow will present:
- The role of cannabis in prostate cancer treatment
- The evolving medical cannabis landscape in South Africa
Her focus will be on fostering global partnerships and providing clinical leadership for pharmaceutical cannabis formulation.
Breakthrough Findings from Clinical Trials
Dr. Gallow’s clinical trials concluded on 30 August 2024 and are under review by the South African Medical Journal. The primary objective was to examine cannabis as a potential opioid replacement for pain management in South Africa. Remarkably, 93% of participants transitioned off opioids by month six, showing improved sleep and quality of life.
Key findings included:
- A temporary rise in anxiety during the initial two months due to opioid withdrawal.
- Improved mobility and reduced pain in multiple sclerosis patients.
- Enhanced appetite and reduced anxiety in cancer patients.
- Unique cases of patients with traumatic brain injuries reporting dreams for the first time.
Next Steps: Global Clinical Trials
Dr. Gallow’s journey continues with Phase 2 and 3 trials in Costa Rica. Collaborating with top medical schools, these trials will test the safety and efficacy of cannabis formulas, with randomized, blinded studies planned across multiple centers.
Driving Medical Cannabis Training and Awareness
Beyond research, Dr. Gallow is committed to global medical cannabis education. Her training programs, accredited by the HPCSA and UCT, offer 25 CPD points to medical doctors. She has already trained dozens of doctors worldwide and holds significant positions at Tshwane University of Technology and the University of Pretoria.
South Africa’s Cannabis Landscape: Opportunities and Challenges
While South Africa boasts expertise in cannabis cultivation and medicinal use, regulatory uncertainties persist. Dr. Gallow emphasizes the need for clearer legal frameworks to curb illicit cannabis shops and ensure consumer safety. Addressing these issues is vital for unlocking the economic potential of the cannabis industry.
The Controversial Section 21 Debate
Dr. Gallow critiques Section 21 of the Medicines Act, stating that it is often misused and fails to serve many patients who could benefit. She calls for:
- Greater oversight and transparency
- A patient-centered approach for better accessibility
Profound Moments in Cannabis Research
For Dr. Gallow, the most remarkable moment was witnessing Stage 4 cancer patients achieve remission within three months of starting cannabis protocols. Such life-changing results continue to fuel her dedication to advancing medical cannabis research globally.
Final Thoughts
Dr. Shiksha Gallow’s pioneering research, combined with her global advocacy, positions her as a key figure in shaping South Africa’s medical cannabis future. With upcoming clinical trials in Costa Rica and strategic international partnerships, her work promises to redefine the global landscape of medical cannabis research.